ESMO 2024 Insights: Final OS from the ATALANTE/ENGOT-ov29 Trial Evaluating Atz vs. Placebo with Standard Cx + Bev in Ovarian Cancer Patients with Platinum-Sensitive Relapse

0 views
September 26, 2024
0 Comments
Login to view comments. Click here to Login